 Connection
Eduardo Davila to Antineoplastic Agents
This is a "connection" page, showing publications Eduardo Davila has written about Antineoplastic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.612 |
|
|
|
-
Li Z, Younger K, Gartenhaus R, Joseph AM, Hu F, Baer MR, Brown P, Davila E. Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies. J Clin Invest. 2015 Mar 02; 125(3):1081-97.
Score: 0.208
-
Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol. 2013 Jun; 93(6):847-63.
Score: 0.182
-
Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z, Davila E. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012 Dec 01; 18(23):6436-45.
Score: 0.177
-
Guha P, Kaptan E, Bandyopadhyaya G, Kaczanowska S, Davila E, Thompson K, Martin SS, Kalvakolanu DV, Vasta GR, Ahmed H. Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis. Proc Natl Acad Sci U S A. 2013 Mar 26; 110(13):5052-7.
Score: 0.046
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|